AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that its partner, GlaxoSmithKline (GSK) Biologicals, has received approval from the European Commission for Rotarix(R) in the European Union (EU). Rotarix(R) will be the first rotavirus vaccine available to children in Europe for the prevention of gastroenteritis caused by rotavirus. GSK intends to introduce this vaccine throughout Europe now that marketing authorization has been granted.
